235 related articles for article (PubMed ID: 28493811)
1. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
Stinchcombe TE; Zhang Y; Vokes EE; Schiller JH; Bradley JD; Kelly K; Curran WJ; Schild SE; Movsas B; Clamon G; Govindan R; Blumenschein GR; Socinski MA; Ready NE; Akerley WL; Cohen HJ; Pang HH; Wang X
J Clin Oncol; 2017 Sep; 35(25):2885-2892. PubMed ID: 28493811
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
Stinchcombe TE; Fan W; Schild SE; Vokes EE; Bogart J; Le QT; Thomas CR; Edelman MJ; Horn L; Komaki R; Cohen HJ; Kishor Ganti A; Pang H; Wang X
Cancer; 2019 Feb; 125(3):382-390. PubMed ID: 30343497
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
Vokes EE; Crawford J; Bogart J; Socinski MA; Clamon G; Green MR
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5045s-5050s. PubMed ID: 16000612
[TBL] [Abstract][Full Text] [Related]
5. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
Park JE; Hong KS; Choi SH; Lee SY; Shin KC; Jang JG; Kwon YS; Park SH; Choi KJ; Jung CY; Eom JS; Kim S; Seol HY; Kim J; Kim I; Park JH; Kim TH; Ahn JH
Clin Lung Cancer; 2024 Jun; 25(4):354-364. PubMed ID: 38503590
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.
Santana-Davila R; Devisetty K; Szabo A; Sparapani R; Arce-Lara C; Gore EM; Moran A; Williams CD; Kelley MJ; Whittle J
J Clin Oncol; 2015 Feb; 33(6):567-74. PubMed ID: 25422491
[TBL] [Abstract][Full Text] [Related]
8. Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.
Schild SE; Pang HH; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Wang X
J Thorac Oncol; 2018 Aug; 13(8):1171-1182. PubMed ID: 29689435
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy in non-small cell lung cancer.
O'Rourke N; Roqué I Figuls M; Farré Bernadó N; Macbeth F
Cochrane Database Syst Rev; 2010 Jun; (6):CD002140. PubMed ID: 20556756
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
11. Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.
Logtenberg ME; Tomlow B; Kastelijn EA; Schramel FMNH
Clin Lung Cancer; 2022 Mar; 23(2):116-121. PubMed ID: 35042652
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy in non-small cell lung cancer.
Rowell NP; O'rourke NP
Cochrane Database Syst Rev; 2004 Oct; (4):CD002140. PubMed ID: 15495029
[TBL] [Abstract][Full Text] [Related]
13. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
Takigawa N; Kiura K; Segawa Y; Hotta K; Tamaoki A; Tokuda Y; Nagata T; Watanabe K; Gemba K; Moritaka T; Horita N; Takeda H; Okimoto N; Takemoto M; Matsuo K; Shinkai T; Tabata M; Ueoka H; Kanazawa S; Tanimoto M
J Thorac Oncol; 2011 Jun; 6(6):1087-91. PubMed ID: 21415777
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).
Aridgides PD; Janik A; Bogart JA; Duffy S; Rosenbaum P; Gajra A
Clin Lung Cancer; 2013 Nov; 14(6):674-9. PubMed ID: 23891240
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
16. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
[TBL] [Abstract][Full Text] [Related]
17. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.
Miller ED; Fisher JL; Haglund KE; Grecula JC; Xu-Welliver M; Bertino EM; He K; Shields PG; Carbone DP; Williams TM; Otterson GA; Bazan JG
J Thorac Oncol; 2018 Mar; 13(3):426-435. PubMed ID: 29326090
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
Vokes EE; Herndon JE; Kelley MJ; Cicchetti MG; Ramnath N; Neill H; Atkins JN; Watson DM; Akerley W; Green MR;
J Clin Oncol; 2007 May; 25(13):1698-704. PubMed ID: 17404369
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Casal Rubio J; Fírvida-Pérez JL; Lázaro-Quintela M; Barón-Duarte FJ; Alonso-Jáudenes G; Santomé L; Afonso-Afonso FJ; Amenedo M; Huidobro G; Campos-Balea B; López-Vázquez MD; Vázquez S
Cancer Chemother Pharmacol; 2014 Mar; 73(3):451-7. PubMed ID: 24352251
[TBL] [Abstract][Full Text] [Related]
20. Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Schild SE; Fan W; Stinchcombe TE; Vokes EE; Ramalingam SS; Bradley JD; Kelly K; Pang HH; Wang X
J Thorac Oncol; 2019 Feb; 14(2):298-303. PubMed ID: 30292852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
